Abstract
Recent empirical studies and analyses have heightened interest in the use of expanded antiretroviral therapy (ART) for prevention of HIV transmission. However, ART is expensive, approximately $600 per person per year, raising issues of the cost and cost-effectiveness of ambitious ART expansion. The goal of this review is to equip the reader with the conceptual tools and substantive background needed to understand and evaluate the policy and programmatic implications of cost-effectiveness assessments of ART for prevention. We provide this review in six sections. We start by introducing and explaining basic concepts of health economics as they relate to this issue, including resources, costs, health metrics (such as Disability-Adjusted Life Years), and different types of economic analysis. We then review research on the cost and cost-effectiveness of ART as treatment, and on the cost-effectiveness of traditional HIV prevention. We describe critical issues in the epidemic impact of ART, such as suppression of transmission and the role of the acute phase of infection. We then present a conceptual model for conducting and interpreting cost-effectiveness analyses of ART as prevention, and review the existing preliminary estimates in this area. We end with a discussion of future directions for programmatic demonstrations and evaluation.
Keywords: Antiretroviral therapy, cost analysis, cost-effectiveness, economics, HIV prevention, HPTN, Cost-effectiveness analysis, Quality-Adjusted Life Years, ”, ART, CD4
Current HIV Research
Title: Cost-Effectiveness of Antiretroviral Therapy for Prevention
Volume: 9 Issue: 6
Author(s): James G. Kahn, Elliot A. Marseille, Rod Bennett, Brian G. Williams and Reuben Granich
Affiliation:
Keywords: Antiretroviral therapy, cost analysis, cost-effectiveness, economics, HIV prevention, HPTN, Cost-effectiveness analysis, Quality-Adjusted Life Years, ”, ART, CD4
Abstract: Recent empirical studies and analyses have heightened interest in the use of expanded antiretroviral therapy (ART) for prevention of HIV transmission. However, ART is expensive, approximately $600 per person per year, raising issues of the cost and cost-effectiveness of ambitious ART expansion. The goal of this review is to equip the reader with the conceptual tools and substantive background needed to understand and evaluate the policy and programmatic implications of cost-effectiveness assessments of ART for prevention. We provide this review in six sections. We start by introducing and explaining basic concepts of health economics as they relate to this issue, including resources, costs, health metrics (such as Disability-Adjusted Life Years), and different types of economic analysis. We then review research on the cost and cost-effectiveness of ART as treatment, and on the cost-effectiveness of traditional HIV prevention. We describe critical issues in the epidemic impact of ART, such as suppression of transmission and the role of the acute phase of infection. We then present a conceptual model for conducting and interpreting cost-effectiveness analyses of ART as prevention, and review the existing preliminary estimates in this area. We end with a discussion of future directions for programmatic demonstrations and evaluation.
Export Options
About this article
Cite this article as:
G. Kahn James, A. Marseille Elliot, Bennett Rod, G. Williams Brian and Granich Reuben, Cost-Effectiveness of Antiretroviral Therapy for Prevention, Current HIV Research 2011; 9 (6) . https://dx.doi.org/10.2174/157016211798038542
DOI https://dx.doi.org/10.2174/157016211798038542 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytokines as Regulators of Atherosclerosis in Murine Models
Current Drug Targets Selective Elevation of Circulating CCL2/MCP1 Levels in Patients with Longstanding Post-vaccinal Macrophagic Myofasciitis and ASIA
Current Medicinal Chemistry Development of Neurochemical Normalization (“Agonist Substitution”) Therapeutics for Stimulant Abuse: Focus on the Dopamine Uptake Inhibitor, GBR12909
Current Medicinal Chemistry - Central Nervous System Agents Prediction of Small Molecules Metabolic Pathways Based on Functional Group Composition
Protein & Peptide Letters Advances in TB Vaccinology
Current Respiratory Medicine Reviews Plant Defensins and Defensin-Like Peptides - Biological Activities and Biotechnological Applications
Current Pharmaceutical Design Nutritional and Therapeutic Potential of Garlic and Onion (Allium sp.)
Current Nutrition & Food Science Modulation of Proinflammatory Bacteria- and Lipid-Coupled Intracellular Signaling Pathways in a Transwell Triple Co-Culture Model by Commensal Bifidobacterium Animalis R101-8
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Promising Therapy of XDR-TB/MDR-TB with Thioridazine an Inhibitor of Bacterial Efflux Pumps
Current Drug Targets Antitubercular Potential of Novel Isoxazole Encompassed 1, 2, 4- Triazoles: Design, Synthesis, Molecular Docking Study and Evaluation of Antitubercular Activity
Anti-Infective Agents From Protein-Protein Interactions to Rational Drug Design: Are Computational Methods Up to the Challenge?
Current Topics in Medicinal Chemistry N-heterocycles: Recent Advances in Biological Applications
Mini-Reviews in Organic Chemistry 4,6-diaryl Pyrimidones as Constrained Chalcone Analogues: Design, Synthesis and Evaluation as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Efflux Pump and its Inhibitors: Novel Targets to Combat Drug Resistance
Anti-Infective Agents Quality by Design Approach for Development and Optimization of Rifampicin Loaded Bovine Serum Albumin Nanoparticles and Characterization
Current Drug Delivery Patents Related to Pathogenic Human Coronaviruses
Recent Patents on Biotechnology Recent Developments in Patents Targeting Toll-Like Receptor Genes
Recent Patents on DNA & Gene Sequences Editorial [ Carbonic Anhydrases as Drug Targets Executive Editor: Claudiu T. Supuran ]
Current Pharmaceutical Design Enzyme Inhibition by Usnic Acids
Current Enzyme Inhibition Women’s Health in Central America: The Complexity of Issues and the Need to Focus on Indigenous Healthcare
Current Women`s Health Reviews